# A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

> **NCT00428220** · NA · COMPLETED · sponsor: **Pfizer** · enrollment: 223 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Advanced Breast Cancer
- Metastatic Castration Resistant Prostate Cancer
- Metastatic Renal Cell Cancer
- Non-Small Cell Lung Cancer
- Thyroid Cancer
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Advanced Gastric Cancer
- Gastrointestinal Stromal Tumor
- Hepatocellular Carcinoma
- Pancreatic Islet Cell Carcinoma
- Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** sunitinib

## Key facts

- **NCT ID:** NCT00428220
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428220, "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00428220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*